Editorial: New and Emerging Lipid-lowering Therapies for Reducing Cardiovascular Risk: Beyond Statins

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jan 30

PMID 38287985

Authors

Fei Luo

Liqing Yu

Xunde Xian

Bo Shan

Avash Das

Affiliations

Soon will be listed here.

References

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

Ferrari R, Catapano A . Residual cardiovascular risk. Eur Heart J Suppl. 2017; 18(Suppl C):C1. DOI: 10.1093/eurheartj/suw010. View

Gaudet D, Alexander V, Baker B, Brisson D, Tremblay K, Singleton W . Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015; 373(5):438-47. DOI: 10.1056/NEJMoa1400283. View

Luo Q, Chen J, Su Y, Wu P, Wang J, Fang Z . Correlation between serum soluble ASGR1 concentration and low-density lipoprotein cholesterol levels: a cross-sectional study. Lipids Health Dis. 2023; 22(1):142. PMC: 10476293. DOI: 10.1186/s12944-023-01910-3. View

Luo F, Das A, Fang Z . Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2021; 384(6):e17. DOI: 10.1056/NEJMc2033612. View

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A . Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2023; 149(5):354-362. PMC: 10815002. DOI: 10.1161/CIRCULATIONAHA.122.063460. View

Raal F, Rosenson R, Reeskamp L, Hovingh G, Kastelein J, Rubba P . Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 383(8):711-720. DOI: 10.1056/NEJMoa2004215. View

Choi D, Malick W, Koenig W, Rader D, Rosenson R . Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3. J Am Coll Cardiol. 2023; 81(16):1621-1632. DOI: 10.1016/j.jacc.2023.02.038. View

10.

Luo F, Das A, Khetarpal S, Fang Z, Zelniker T, Rosenson R . ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends Cardiovasc Med. 2023; 34(4):215-222. DOI: 10.1016/j.tcm.2023.01.008. View

11.

Cuchel M, Meagher E, du Toit Theron H, Blom D, Marais A, Hegele R . Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2012; 381(9860):40-6. PMC: 4587657. DOI: 10.1016/S0140-6736(12)61731-0. View

12.

Nurmohamed N, Navar A, Kastelein J . New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2021; 77(12):1564-1575. DOI: 10.1016/j.jacc.2020.11.079. View

13.

Luo Q, Tang Z, Wu P, Chen Z, Fang Z, Luo F . A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022. Front Endocrinol (Lausanne). 2023; 14:1218968. PMC: 10716461. DOI: 10.3389/fendo.2023.1218968. View